TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29648726
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of alendronate sodium (70 mg)
Study: 29648726
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of alendronate sodium (70 mg)
Study: 19640384
Drug: Plasma von
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma von Willebrand factor and soluble vascular adhesion molecule-1
Study: 15167309
Drug: 17beta‐estradiol 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17beta‐estradiol 2 mg + norethisterone acetate 1 mg (E2/NETA)
Study: 15167309
Drug: Raloxifene HCL
Normalized name: raloxifene HCl
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene HCL 60 mg
Study: 12518494
Drug: Discus Dental
Normalized name: Sus scrofa intervertebral disc preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discus Dental Zoom! Chairside System (25% hydrogen peroxide whitening gel)
Study: 12518494
Drug: Opalescence Xtra
Normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Opalescence Xtra Boost Kit (38% hydrogen peroxide whitening gel)
Study: 9811286
Drug: Garlic extract
Normalized name: Garlic Extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic extract (Kwai, 300 mg, 3 times a day)
Study: 7815239
Drug: High‐dose corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: High‐dose corticosteroids
Study: 2576361
Drug: Picumast dihydrochloride
Normalized name: Levocetirizine Dihydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picumast dihydrochloride 2 mg/d
Study: 2576361
Drug: Picumast dihydrochloride
Normalized name: Levocetirizine Dihydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picumast dihydrochloride 4 mg/d
Study: 27881709
Drug: Metformin use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin use in patients with diabetes mellitus (n = 115)
Study: 27881709
Drug: Non-users of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-users of metformin (DM patients without metformin use and non-DM patients)
Study: 20163275
Drug: Rotigotine transdermal
Normalized name: Rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine transdermal patch (1 to 3 mg/24 h)
Study: 8626365
Drug: Nefazodone, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone, 100 mg b.i.d. starting dose, adjusted to 300-500 mg daily
Study: 1425394
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g dextrose
Study: 2866168
Drug: Sinemet (L-DOPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinemet (L-DOPA plus carbidopa) with haloperidol
Study: 26409030
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg sublingual buprenorphine
Study: 20617288
Drug: Fosinopril (ACE-inhibitor)
DrugBank: Fosinopril (DB00492)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosinopril (ACE-inhibitor) for 6 months
Study: 17852925
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (r-hGH) 4 mg daily
Study: 12450890
Drug: Lactobacillus plantarum
Normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus plantarum 299v (5 x 10(7) colony-forming units/mL) in a rose-hip drink, 400 mL/d for 6 weeks
Study: 12450890
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (rose-hip drink without bacteria), 400 mL/d for 6 weeks
Study: 8630585
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (NO) at 17.8 ± 2.7 ppm
Study: 1746300
Drug: Physician-administered genogram
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physician-administered genogram (PAGE)
Study: 1746300
Drug: Self-administered genogram
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered genogram (SAGE)
Study: 19678927
Drug: Breast Conservative
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast Conservative Therapy (BCT)
Study: 15880962
Drug: Sorbitol (G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbitol (G group)
Study: 12458352
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (before neuraminidase inhibitors)
Study: 9792309
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (AmBisome, 5 mg/kg/d)
Study: 9792309
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B deoxycholate (AmB, 1 mg/kg/d)
Study: 6330425
Drug: Zinc therapy
Normalized name: PYRITHIONE ZINC 2 g in 100 g TOPICAL SOAP [Zinc Therapy]
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc therapy using a nonproprietary zinc dialysate
Study: 25245767
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (IVL) - 2% intravenously (1.5 mg/kg bolus, 2 mg/kg/h infusion)
Study: 25245767
Drug: Lumbar epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar epidural lidocaine analgesia (LEA) - lidocaine epidurally (1.5 mg/kg bolus, 2 mg/kg/h infusion)
Study: 22234019
Drug: Intravenous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous low-dose ketamine (0.1 mg/kg as a preincisional bolus followed by a continuous infusion of 0.05 mg/kg/h)
Study: 9613405
Drug: Felodipine 5
Normalized name: felodipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 5 mg administered the evening and morning before surgery
Study: 8512909
Drug: Intramuscular and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular and oral ketorolac
Study: 3450519
Drug: Nifedipine therapy
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine therapy for 2 and 14-16 weeks
Study: 25491116
Drug: 0.05% desonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% desonide cream
Study: 18257177
Drug: Prozac (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prozac (20 mg/d)
Study: 15678251
Drug: Topical liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical liposomal heparin spraygel (LHSG) (Lipohep Forte Spraygel, 4 puffs of 458 IU tid, n = 22)
Study: 15678251
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) (Clexane 40 mg once a day, n = 24)
Study: 12790214
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine 10 mg + neostigmine 25 microg in dextrose 5%, 1 mL, total volume 3 mL (Group 2)
Study: 12790214
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine 10 mg + neostigmine 50 microg in dextrose 5%, 1 mL, total volume 3 mL (Group 3)
Study: 12790214
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine 10 mg + dextrose 5%, 1 mL, total volume 3 mL (Group 1)
Study: 10376255
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol maleate in gel-forming solution
Study: 3900727
Drug: Intramuscular lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular lidocaine (400 mg)
Study: 23008301
Drug: Short-course (SC)
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course (SC) radiotherapy: 5 × 5 Gy in 1 week, early surgery, and six courses of adjuvant chemotherapy
Study: 23008301
Drug: Long-course (LC)
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-course (LC) chemoradiation: 50.4 Gy, 1.8 Gy/fraction, in 5.5 weeks, with continuous infusional fluorouracil 225 mg/m(2) per day, surgery in 4 to 6 weeks, and four courses of chemotherapy
Study: 19859670
Drug: Advanced Standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced Standard Treatment (AST) - rheological therapy complemented by distraction and relaxation training
Study: 19859670
Drug: Standard Treatment
Normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Treatment (ST) - rheological therapy
Study: 17931375
Drug: 10 seconds
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 seconds injection duration
Study: 17931375
Drug: 30 seconds
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 seconds injection duration
Study: 15950671
Drug: Extended transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended transdermal contraception (ORTHO EVRA) used in an extended regimen (84 days)
Study: 15046711
Drug: Liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal doxorubicin 50 mg/m2
Study: 15046711
Drug: Doxorubicin 50
Normalized name: DOXOrubicin 50 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 50 mg/m2 (first dose only)
Study: 15046711
Drug: Liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal doxorubicin 50 mg/m2 (subsequent cycles)
Study: 7572056
Drug: Antiepileptic drugs
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic drugs (AED) treatment (carbamazepine, oxcarbazepine, sodium‐valproate, phenobarbital, phenytoin)
Study: 7572056
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of AED monotherapy (carbamazepine or sodium‐valproate)
Study: 7572056
Drug: Switch from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch from phenytoin to carbamazepine monotherapy
Study: 2338113
Drug: Renzapride 2
Normalized name: Renzapride
DrugBank: Renzapride (DB04917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renzapride 2 mg
Study: 2338113
Drug: Renzapride 5
Normalized name: Renzapride
DrugBank: Renzapride (DB04917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renzapride 5 mg
Study: 2338113
Drug: Renzapride 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renzapride 0.2 to 5 mg
Study: 320930
Drug: Methyltestosterone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyltestosterone (10 mg daily in linguet form)
Study: 30535714
Drug: Submucosal autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submucosal autologous platelet-rich plasma injection (PRP injection group)
Study: 30535714
Drug: Submucosal normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submucosal normal saline injection (control group)
Study: 28486595
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg ITM
Study: 28486595
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg ITM
Study: 28486595
Drug: Choice of
Normalized name: HYDROGEN PEROXIDE 30 mg in 1 mL TOPICAL LIQUID [MediChoice of Hydrogen Peroxide 3 10 Volume]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choice of ITM dose (either 100 or 200 μg)
Study: 23009581
Drug: Regular radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular radiation therapy
Study: 17982752
Drug: Antioxidant therapy
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant therapy (NAC 600 mg and vitamins-minerals)
Study: 17982752
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no adjunctive medical therapy)
Study: 12950526
Drug: d,l‐sotalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: d,l‐sotalol
Study: 10392481
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 mg twice a day
Study: 8912765
Drug: Rifampicin (RMP)
Normalized name: rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifampicin (RMP) 600 mg/d
Study: 8912765
Drug: Rifabutin (RBT)
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifabutin (RBT) 300 mg/d
Study: 1652386
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and subcutaneous salmon calcitonin
Study: 7046707
Drug: Argon laser
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argon laser photocoagulation treatment group
Study: 28371488
Drug: Innovative film‐coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Innovative film‐coated warfarin sodium tablets
Study: 28371488
Drug: Marketed sugar‐coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed sugar‐coated warfarin sodium tablets
Study: 21968280
Drug: Relaxation training
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation training program (mini mp3 player with 13-min relaxation audio program, followed daily)
Study: 14762496
Drug: Midazolam (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (1.0 mg/kg)
Study: 14762496
Drug: Midazolam (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.75 mg/kg) plus Hydroxyzine (2.0 mg/kg)
Study: 8846278
Drug: Continuous Morphine
Normalized name: morphine sulfate Oral Suspension [MST Continus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Morphine Infusion (CMI)
Study: 1999715
Drug: Oral cryotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cryotherapy during chemotherapy administration
Study: 6635761
Drug: Praziquantel 15
Normalized name: praziquantel 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel 15 mg/kg
Study: 24945286
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (808 nm laser irradiation as 4 J/point for 20 s over ipsilateral three nerve roots and 0.1 J/cm2 for 5 min in tangential scanning mode)
Study: 22737868
Drug: Sanchi Tong
Normalized name: beef tongue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sanchi Tong Shu capsule
Study: 22737868
Drug: Betahistine mesilate
Normalized name: Betahistine mesilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine mesilate tablets
Study: 16050412
Drug: Elemental calcium
Normalized name: Elemental calcium
DrugBank: Calcium (DB01373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elemental calcium (max 1000 to 1500 mg/day)
Study: 8699054
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of RRV‐TV vaccine
Study: 8699054
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of RRV‐TV vaccine
Study: 8699054
Drug: One and
Normalized name: oxycodone and naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: One and three doses of RRV‐TV vaccine
Study: 7044294
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of amantadine
Study: 7044294
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of rimantadine
Study: 7044294
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of amantadine + 4 mg of chlorpheniramine
Study: 30941562
Drug: Leuprolide mesylate
Normalized name: Leuprolide Mesylate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide mesylate subcutaneous injectable suspension (LMIS) 50 mg
Study: 29609146
Drug: Group psychotherapeutic
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group psychotherapeutic intervention based on cognitive‐behavioral therapy (CBT); 8 weekly, semi‐structured group meetings.
Study: 27055643
Drug: Neostigmine (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (0.03 mg/kg) and Atropine (0.01 mg/kg)
Study: 24138922
Drug: Amphetamine challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine challenge in stimulant drug-naïve healthy control subjects
Study: 24138922
Drug: Amphetamine challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine challenge in subjects matched to high-risk group on personal drug use
Study: 22578529
Drug: Puerarin (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Puerarin (1200 mg daily)
Study: 17468814
Drug: Sivelestat (neutrophil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sivelestat (neutrophil elastase inhibitor)
Study: 11913291
Drug: 6.5% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.5% hydrogen peroxide tooth-whitening gel strip, used for 30 minutes per day, twice daily for 2 months
Study: 7695301
Drug: DU-6859a 25
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DU-6859a 25 mg
Study: 7695301
Drug: DU-6859a 50
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DU-6859a 50 mg
Study: 7695301
Drug: DU-6859a 100
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DU-6859a 100 mg
Study: 7695301
Drug: DU-6859a 200
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DU-6859a 200 mg
Study: 7695301
Drug: DU-6859a 100
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DU-6859a 100 mg three times a day for 6 days plus once a day on the 7th day
Study: 7695301
Drug: DU-6859a 50
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DU-6859a 50 mg every 12 h for 13 doses
Study: 7695301
Drug: DU-6859a (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: DU-6859a (all doses)
Study: 2468957
Drug: isradipine 5-10
Normalized name: isradipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: isradipine 5-10 mg twice daily
Study: 407914
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) feeding of amino acids and calories
Study: 30664548
Drug: Driving pressure-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Driving pressure-guided ventilation (n = 145): tidal volume 6 ml/kg of ideal body weight, individualized PEEP to minimize driving pressure.
Study: 30664548
Drug: Conventional protective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional protective ventilation (n = 147): tidal volume 6 ml/kg of ideal body weight, PEEP 5 cm H2O, and recruitment maneuver.
Study: 24010572
Drug: 80/480 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80/480 mg tablet
Study: 24010572
Drug: 60/360 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60/360 mg tablet
Study: 24010572
Drug: Four standard
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four standard tablets
Study: 24010572
Drug: Three standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three standard tablets
Study: 21324142
Drug: Neoadjuvant imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant imatinib (IM) treatment
Study: 21324142
Drug: Surgical resection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical resection followed by continuous IM treatment
Study: 18851855
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl cysteine (NAC) 0.6 g per day plus 17-hydroxyprogesterone caproate (17-OHPC)
Study: 15457023
Drug: Subcutaneous infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous infiltration block
Study: 9355081
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with antilymphocyte antibodies
Study: 9355081
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (cyclosporine, azathioprine, and prednisone)
Study: 8202978
Drug: Electromyographic biofeedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electromyographic biofeedback treatment together with physical therapy
Study: 27889390
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg GSE
Study: 27889390
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg GSE
Study: 27889390
Drug: 2500 mg
Normalized name: inulin 2500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2500 mg GSE
Study: 25214069
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZOL) 5 mg annually for up to three injections (years 4, 5, and 6)
Study: 23739813
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (0.00375 mmol/kg)
Study: 23739813
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose (0.0075 mmol/kg)
Study: 23739813
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (0.0150 mmol/kg)
Study: 18813412
Drug: Ginger capsules
DrugBank: Ginger (DB10344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger capsules 3 g/day in 3 divided doses for 45 days
Study: 18813412
Drug: Placebo (lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose capsule 3 g/day in 3 divided doses for 45 days)
Study: 17059329
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MMG and CEA markers
Study: 15312092
Drug: Machined surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Machined surface implants
Study: 15312092
Drug: Rough-surface Tioblast
Normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rough-surface Tioblast implants
Study: 9313757
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous insulin infusion (1.2 +/- 0.4 U.kg‐1.day‐1)
Study: 9313757
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (0.4 +/- 0.1 U.kg‐1.day‐1)